Last €57.71 EUR
Change Today +1.01 / 1.78%
Volume 0.0
UNC On Other Exchanges
EN Brussels
As of 2:08 AM 04/17/14 All times are local (Market data is delayed by at least 15 minutes).

ucb sa (UNC) Snapshot

Previous Close
Day High
Day Low
52 Week High
03/6/14 - €59.08
52 Week Low
06/25/13 - €38.12
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield
Current Stock Chart for UCB SA (UNC)

Related News

No related news articles were found.

ucb sa (UNC) Related Businessweek News

No Related Businessweek News Found

ucb sa (UNC) Details

UCB S.A., a biopharmaceutical company, discovers and develops therapies primarily for central nervous system (CNS) disorders and immunology diseases worldwide. Its CNS products include Vimpat and Keppra for epilepsy, and Neupro for Parkinson’s disease and restless legs syndrome; Nootropil for regulating cerebral functions; and Metadate CD for attention deficit hyperactivity disorder. The company is developing Vimpat, which is under Phase III clinical trials for epilepsy-monotherapy; and brivaracetam for epilepsy-adjunctive therapy, as well as developing Vimpat that has completed Phase II clinical trials for epilepsy-paediatric adjunctive therapy, and epilepsy adjunctive therapy. It is also developing UCB0942, which has completed Phase I clinical trials for refractory epilepsy. The company provides immunology products, such as Cimzia for Crohn's disease and rheumatoid arthritis; Xyzal and Zyrtec for allergies; Tussionex for respiratory disease; and Lortab for pain relief. It is also developing CDP7657 that has completed Phase I clinical trials for systemic lupus erythematosus; and UCB4940, which is under Phase I clinical trial for immunological diseases. The company has a strategic collaboration with Five Prime Therapeutics, Inc. for the discovery of biologics targets and therapeutics in the areas of fibrosis-related inflammatory diseases and CNS disorders; and a strategic partnership with Sanofi for the discovery and development of anti-inflammatory small molecules. UCB S.A. was founded in 1928 and is headquartered in Brussels, Belgium.

8,224 Employees
Last Reported Date: 02/28/14
Founded in 1928

ucb sa (UNC) Top Compensated Officers

Chief Executive Officer and Executive Directo...
Total Annual Compensation: €2.1M
Compensation as of Fiscal Year 2013.

ucb sa (UNC) Key Developments

UCB Proposes Amendment to the Articles of Association

UCB announced that at the AGM to be held on April 24, 2014, the shareholders will consider amendment to the articles of association.

UCB SA Presents at Exane 16th Annual Healthcare Conference, Mar-26-2014

UCB SA Presents at Exane 16th Annual Healthcare Conference, Mar-26-2014 . Venue: Paris, France.

UCB SA Presents at KBC Healthcare Conference, Mar-20-2014 01:30 PM

UCB SA Presents at KBC Healthcare Conference, Mar-20-2014 01:30 PM. Venue: KBC Building, Grand Place, Grote Markt 17, 1000 Brussels, Belgium. Speakers: Alexandra Deschner, IR Director, Antje Witte, Vice President of Investor Relations.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
UNC:GR €57.71 EUR +1.01

UNC Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Grifols SA €36.78 EUR +0.375
Hospira Inc $42.84 USD -0.16
Lonza Group AG SFr.85.30 CHF +1.00
Mylan Inc/PA $46.92 USD -0.29
Sigma-Aldrich Corp $94.07 USD +0.05
View Industry Companies

Industry Analysis


Industry Average

Valuation UNC Industry Range
Price/Earnings 52.4x
Price/Sales 3.1x
Price/Book 2.3x
Price/Cash Flow 54.6x
TEV/Sales 2.3x

Post a JobJobs

View all jobs

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact UCB SA, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at